Shionogi & Co., Ltd. achieved sales of \u00a5499.7 billion (14.0% increase) for the fiscal year ending March 2026, with operating profit of \u00a5166.7 billion (6.5% increase) and net income attributable to owners of the parent of \u00a5205.9 billion (20.4% increase), setting new records. The company is strengthening sales and R&D investments domestically and internationally, expecting continued high growth this period.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4507-20260512-01.pdf","jir_short_summary":"Shionogi & Co., Ltd. achieved sales of \u00a5499.7 billion (14.0% increase) for the fiscal year ending March 2026, with operating profit of \u00a5166.7 billion (6.5% increase) and net income attributable to owners of the parent of \u00a5205.9 billion (20.4% increase), setting new records. The company is strengthening sales and R&D investments domestically and internationally, expecting continued high growth this period.","jir_summary":"### Summary of Business Performance\nShionogi & Co., Ltd. recorded a new high for the fiscal year ending March 2026 with sales of \u00a5499.7 billion (up 14.0% YoY) and operating income of \u00a5166.7 billion (up 6.5%). The expansion of pharmaceutical sales domestically and internationally, along with M&A-driven business expansion, has actively advanced R&D investments. Particularly, new drugs in infectious disease and QOL disorder areas have progressed through development and approval, projecting continued high growth in the next period. Overseas sales continues steadily, strengthening the revenue foundation through royalty income and new drug launches.\n\n### Future Outlook and Impact on Shareholders\nThe consolidated earnings forecast for the fiscal year ending March 2027 projects sales of \u00a5700.0 billion (up 40.1%) and net income of \u00a521.0 billion (up 2.4%). Stable income from infectious disease drugs and accelerated new drug development are expected to sustain high growth. Plans include stock splits and increased dividends, aiming to balance shareholder returns with business expansion. By advancing research investments and global development, the company aims for sustainable growth.","jir_financial_highlights":"Sales Revenue: \u00a5499.7 billion (Up 14.0% YoY)\nOperating Income: \u00a5166.7 billion (Up 6.5% YoY)\nNet Income Attributable to Owners of Parent: \u00a5205.9 billion (Up 20.4% YoY)\nTotal Revenue: \u00a5499.7 billion (14.0% increase)\nTotal Assets: \u00a52,576.8 billion (Increase from previous fiscal year)","jir_category":"","jir_hashtags":"#Shionogi, #IRResults, #JapaneseStocks","jir_key_figures":"Sales Revenue: \u00a5499.7 billion (up 14.0% YoY)\nNet Income Attributable to Owners of Parent: \u00a5205.9 billion (up 20.4%)\nTotal Assets: \u00a52.5768 trillion","jir_meta_title":"\u3010Shionogi & Co., Ltd.\u30112026 Fiscal Year Earnings\uff5cSales of \u00a5499.7 billion, a record high","jir_meta_description":"Shionogi & Co., Ltd. achieved sales of \u00a5499.7 billion (up 14.0%) for the fiscal year ending March 2026, with expectations of continued high growth. The company emphasizes research investments and overseas expansion, with a focus on sustainable growth. This report explains the financial results.","jir_og_title":"\u3010Shionogi & Co., Ltd.\u30112026 Fiscal Year Earnings\uff5cSales of \u00a5499.7 billion (up 14.0%)","jir_og_description":"Shionogi & Co., Ltd. achieved record-high sales and profits in the fiscal year ending March 2026. The company anticipates continued high growth and is promoting R&D and global expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48152","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n